Cargando…

Switch from Olanzapine Long-Acting Injectable to its Oral Equivalent during COVID-19 Pandemic: a Real World Observational Study

Schizophrenia is a psychiatric condition with chronic evolution, one of the most disabling diseases. The main cause for the disease’s progression is considered to be the lack of compliance with the treatment. Long-acting injectable antipsychotics (LAIs) are an important treatment option for patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miron, Ana-Aliana, Teodorescu, Andreea, Ifteni, Petru, Irimie, Claudia Alexandrina, Dima, Lorena, Petric, Paula-Simina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888267/ https://www.ncbi.nlm.nih.gov/pubmed/35235126 http://dx.doi.org/10.1007/s11126-021-09924-9

Ejemplares similares

Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics—An Observational Study
por: Miron, Ana Aliana, et al.
Publicado: (2023)

Rating Opportunity for Long-Acting Injectable Antipsychotic Initiation Index (ROLIN)
por: Ifteni, Petru, et al.
Publicado: (2021)

Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection
por: Moga, Silvia, et al.
Publicado: (2022)

Long-acting injectable antipsychotics treatment during COVID-19 pandemic – A new challenge
por: Ifteni, Petru, et al.
Publicado: (2020)

Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania
por: Miron, Ana A., et al.
Publicado: (2022)

WHODAS Assessment Feasibility and Mental Health Impact on Functional Disability in Systemic Lupus Erythematosus
por: Duca, Liliana, et al.
Publicado: (2022)

Clozapine Efficacy in a Case of Severe Treatment-Resistant Postpartum Psychosis
por: Teodorescu, Andreea, et al.
Publicado: (2021)

Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment
por: Moga, Silvia, et al.
Publicado: (2021)

Switching bipolar disorder patients treated with clozapine to another antipsychotic medication: a mirror image study
por: Ifteni, Petru, et al.
Publicado: (2017)

Schizophrenia relapse after stopping olanzapine treatment during pregnancy: a case report
por: Ifteni, Petru, et al.
Publicado: (2014)

Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
por: Ciudad, Antonio, et al.
Publicado: (2013)

Association between Inflammation and Thrombotic Pathway Link with Pathogenesis of Depression and Anxiety in SLE Patients
por: Duca, Liliana, et al.
Publicado: (2023)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
por: Lindenmayer, JP
Publicado: (2010)

Pharmacokinetics of olanzapine long-acting injection: the clinical perspective
por: Heres, Stephan, et al.
Publicado: (2014)

Schizophrenia long-acting antipsychotics initiation index (SLAAII)
por: Ifteni, P., et al.
Publicado: (2021)

Dilemma of treating schizophrenia during pregnancy: a Case series and a review of literature
por: Teodorescu, Andreea, et al.
Publicado: (2017)

Delayed identification and diagnosis of Huntington’s disease due to psychiatric symptoms
por: Pascu, Alina Mihaela, et al.
Publicado: (2015)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
por: Wehring, Heidi J., et al.
Publicado: (2011)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
por: Di Lorenzo, Rosaria, et al.
Publicado: (2010)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
por: Citrome, Leslie
Publicado: (2009)

Inpatient prescribing patterns of long-acting injectables and their oral or short-acting injectable equivalent formulations
por: Liu, Yifei, et al.
Publicado: (2023)

A study on blood pressure changes following Olanzapine Long Acting Injection (LAI) in schizophrenia
por: Gakkhar, Shivam, et al.
Publicado: (2022)

An Overview on the Conservative Management of Endometriosis from a Naturopathic Perspective: Phytochemicals and Medicinal Plants
por: Balan, Andreea, et al.
Publicado: (2021)

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases
por: Detke, Holland C, et al.
Publicado: (2010)

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism
por: McDonnell, David P, et al.
Publicado: (2010)

A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection
por: Atkins, Susan, et al.
Publicado: (2014)

IVIVC from Long Acting Olanzapine Microspheres
por: D'Souza, Susan, et al.
Publicado: (2014)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
por: Ascher-Svanum, Haya, et al.
Publicado: (2014)

Within‐drug benefit‐risk evaluation of olanzapine long‐acting injection at one and two years of treatment
por: Detke, Holland C., et al.
Publicado: (2014)

Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice
por: Bushe, Chris J, et al.
Publicado: (2015)

Evaluating adult forensic staff knowledge of olanzapine long-acting injection post injection syndrome: a service improvement project
por: Clark, Annalie, et al.
Publicado: (2021)

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
por: Katagiri, Hideaki, et al.
Publicado: (2018)

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
por: Ascher-Svanum, Haya, et al.
Publicado: (2012)

Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
por: Anand, Ernie, et al.
Publicado: (2016)

Postinjection Delirium/Sedation Syndrome with Olanzapine Depot Injection
por: Sarangula, Sadhvi Mythili, et al.
Publicado: (2016)

Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis
por: Peuskens, Joseph, et al.
Publicado: (2012)

Olanzapine long-acting injection, discontinuation rates and reasons for discontinuation: 10 years’ experience at a UK high-secure hospital
por: Attard, Azizah, et al.
Publicado: (2022)

Acute Metabolic Effects of Olanzapine Depend on Dose and Injection Site
por: Klingerman, Candice M., et al.
Publicado: (2015)

Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
por: Dilla, Tatiana, et al.
Publicado: (2014)

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_rhhtnv9h4s44p9r9kj438ntd2g